Markella V Zanni

List of Publications by Year
in descending order

76 papers	2,757 citations	257450 24 h-index	189892 50 g-index
76 all docs	76 docs citations	76 times ranked	3651 citing authors

#	Article	IF	Citations
1	Arterial Inflammation in Patients With HIV. JAMA - Journal of the American Medical Association, 2012, 308, 379.	7.4	411
2	TNF-Î± Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E146-E150.	3.6	281
3	The Association of Obesity and Cardiometabolic Traits With IncidentÂHFpEF and HFrEF. JACC: Heart Failure, 2018, 6, 701-709.	4.1	254
4	Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. Aids, 2013, 27, 1263-1272.	2.2	115
5	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). American Heart Journal, 2019, 212, 23-35.	2.7	99
6	Risk of coronary heart disease in patients with HIV infection. Nature Reviews Cardiology, 2014, 11, 728-741.	13.7	90
7	Sex Differences in Circulating Biomarkers of Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 74, 1543-1553.	2.8	82
8	Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. Aids, 2017, 31, 797-806.	2.2	74
9	Protease Inhibitors and CardiovascularÂOutcomes in PatientsÂWith HIV and HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 518-530.	2.8	68
10	Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normalâ€weight subjects. Clinical Endocrinology, 2012, 77, 385-390.	2.4	67
11	Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 164-171.	2.1	66
12	Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. JAMA Cardiology, 2016, 1, 474.	6.1	66
13	2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. Aids, 2014, 28, 2061-2070.	2.2	65
14	Elevated ischemic stroke risk among women living with HIV infection. Aids, 2018, 32, 59-67.	2.2	58
15	HIV Infection and HeartÂFailure Outcomes inÂWomen. Journal of the American College of Cardiology, 2017, 69, 107-108.	2.8	49
16	Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation. Current HIV/AIDS Reports, 2017, 14, 220-228.	3.1	49
17	Cardiovascular disease risk among women living with HIV in North America and Europe. Current Opinion in HIV and AIDS, 2017, 12, 585-593.	3.8	43
18	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. American Heart Journal, 2019, 212, 1-12.	2.7	43

#	Article	IF	Citations
19	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Network Open, 2021, 4, e2114923.	5.9	38
20	HIV-Specific Immune Dysregulation and Atherosclerosis. Current HIV/AIDS Reports, 2012, 9, 200-205.	3.1	34
21	Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. Journal of Infectious Diseases, 2017, 215, 1264-1269.	4.0	33
22	Immune Correlates of Diffuse Myocardial Fibrosis and Diastolic Dysfunction Among Aging Women With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2020, 221, 1315-1320.	4.0	33
23	Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. Aids, 2015, 30, 1.	2.2	31
24	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Scientific Reports, 2022, 12, 577.	3.3	27
25	Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations. Current HIV/AIDS Reports, 2019, 16, 371-380.	3.1	26
26	Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. Aids, 2016, 30, 2205-2214.	2.2	25
27	The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus. JACC: Heart Failure, 2019, 7, 759-767.	4.1	25
28	Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center. American Heart Journal, 2019, 210, 39-48.	2.7	23
29	Intramyocardial Triglycerides Among Women With vs Without HIV: Hormonal Correlates and Functional Consequences. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6090-6100.	3.6	21
30	Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	20
31	Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1762-1775.	2.4	20
32	Effects of TNFâ€alpha antagonism on Eâ€selectin in obese subjects with metabolic dysregulation. Clinical Endocrinology, 2010, 73, 48-54.	2.4	19
33	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clinical Infectious Diseases, 2021, 73, 2009-2022.	5.8	19
34	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab537.	0.9	19
35	Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 421-428.	2.1	18
36	Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. Aids, 2019, 33, 229-236.	2.2	18

#	Article	IF	Citations
37	Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infectious Diseases, 2017, 4, ofx227.	0.9	17
38	Myocardial Steatosis Among Antiretroviral Therapyâ€"Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S63-S69.	4.0	17
39	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. Antiviral Therapy, 2014, 19, 805-811.	1.0	16
40	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine, 2018, 35, 58-66.	6.1	16
41	Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S20-S30.	4.0	16
42	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. Journal of Infectious Diseases, 2020, 222, 929-939.	4.0	16
43	Estrogen Sulfotransferase Is Expressed in Subcutaneous Adipose Tissue of Obese Humans in Association with TNF-Î± and SOCS3. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1153-E1158.	3.6	14
44	Increased FDG uptake in association with reduced extremity fat in HIV patients. Antiviral Therapy, 2012, 18, 243-248.	1.0	14
45	Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clinical Trials, 2017, 18, 83-91.	2.0	14
46	Cardiovascular Risk Profile of Transgender Women With HIV: A US Health Care Database Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, e39-e41.	2.1	14
47	Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications. Circulation Research, 2022, 130, 578-592.	4.5	13
48	Contribution of the Hormone-Response Elements of the Proximal ApoA-I Promoter, ApoCIII Enhancer, and C/EBP Binding Site of the Proximal ApoA-I Promoter to the Hepatic and Intestinal Expression of the ApoA-I and ApoCIII Genes in Transgenic Mice. Biochemistry, 2004, 43, 5084-5093.	2.5	12
49	Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 41.	0.9	12
50	Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antiviral Therapy, 2017, 23, 1-9.	1.0	11
51	Incidence, Predictors, and Outcomes of Implantable Cardioverterâ€Defibrillator Discharge Among People Living With HIV. Journal of the American Heart Association, 2018, 7, e009857.	3.7	11
52	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. Journal of Infectious Diseases, 2022, 226, 1809-1822.	4.0	11
53	Novel mediators of statin effects on plaque in HIV. Aids, 2018, 32, 867-876.	2.2	9
54	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity, 2020, 28, 749-755.	3.0	9

#	Article	IF	Citations
55	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S8-S19.	4.0	8
56	COVID-19 Vaccination Rates in a Global HIV Cohort. Journal of Infectious Diseases, 2022, 225, 603-607.	4.0	8
57	Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. Clinical Infectious Diseases, 2022, 75, 1324-1333.	5.8	8
58	Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals. Open Forum Infectious Diseases, 2018, 5, ofy326.	0.9	7
59	HDL Cholesterol Efflux Capacity in Newly Diagnosed HIV and Effects of Antiretroviral Therapy. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4250-4259.	3.6	6
60	Effects of Integrase Inhibitorâ€“Based ART on the NLRP3 Inflammasome Among ART-NaÃ¯ve People With HIV. Open Forum Infectious Diseases, 2020, 7, ofaa459.	0.9	6
61	Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2017, 4, ofx083.	0.9	5
62	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. HIV Research and Clinical Practice, 2020, 21, 11-23.	1.1	5
63	Brief Report: Vascular Dysfunction and Monocyte Activation Among Women With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 233-238.	2.1	4
64	Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. Journal of Infectious Diseases, 2020, 222, S31-S40.	4.0	4
65	Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk. Clinical Infectious Diseases, 2022, 75, 1154-1163.	5.8	4
66	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 349-359.	2.1	4
67	Chronic Human Immunodeficiency Virus Infection Is Associated with Accelerated Decline of Forced Expiratory Volume in 1 Second among Women but Not among Men: A Longitudinal Cohort Study in Uganda. Annals of the American Thoracic Society, 2022, 19, 1779-1783.	3.2	4
68	Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy. Clinical Chemistry and Laboratory Medicine, 2003, 41, 411-24.	2.3	3
69	Cardiovascular Disease Risk Among Transgender People with HIV. Current HIV/AIDS Reports, 2021, 18, 407-423.	3.1	3
70	Sleep Apnea and Heart Failure With a Reduced Ejection Fraction Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2018, 67, 447-455.	5.8	2
71	Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. Clinical Infectious Diseases, 2020, 71, 1306-1315.	5.8	2
72	Striving to characterize endocrineâ€“metabolic and immune health risks among transgender women with HIV. Aids, 2019, 33, 919-922.	2.2	1

#	Article	IF	Citations
73	Hot Flashes and Cardiovascular Disease Risk Indices Among Women With HIV. Open Forum Infectious Diseases, 2021, 8, ofab011.	0.9	1
74	A Sex-Stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda. Viruses, 2021, 13, 2135.	3.3	1
75	Reply. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e84-e85.	2.1	0
76	Menopausal Symptoms and Cardiovascular Disease Risk Indices Among Women With HIV. Journal of the Endocrine Society, 2021, 5, A293-A294.	0.2	0